WGc-0201

· West China Hospital

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for WGc-0201, covering 2025-07-22 to 2025-07-22. Get the full timeline:

Most recent: Clinical Trial Update: WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy [Phase 1]